Intelligence Feed event · Equity · 2026-09-12

    Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoY

    Question

    Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoY

    Direct answer

    Eli Lilly's immunology segment reached $2.6 billion in first-half 2026 sales, representing 9% annual growth and 6.1% of firmwide revenue. Portfolio momentum is driven by flagship asset Taltz alongside rollouts of Ebglyss and Omvoh. Lilly continues building depth across oral and targeted immunology through acquired assets from DICE, Morphic, and Merida, broadening revenue exposure beyond its core GLP-1 diabetes and obesity pipeline.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoY”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/eli-lilly-immunology-sales-reach-2-6b-in-h1-2026-rising-9-yoy-5d61d1

    EQUITY
    Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoY
    Eli Lilly's immunology segment reached $2.6 billion in first-half 2026 sales, representing 9% annual growth and 6.1% of firmwide revenue. Portfolio momentum is driven by flagship asset Taltz alongside rollouts of Ebglyss and Omvoh. Lilly continues building depth across oral and targeted immunology through acquired assets from DICE, Morphic, and Merida, broadening revenue exposure beyond its core GLP-1 diabetes and obesity pipeline.
    LLYABBV
    Impact
    59
    SEP 12
    SIG
    85%
    LLYABBV
    Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoY
    Eli Lilly's immunology segment reached $2.6 billion in first-half 2026 sales, representing 9% annual growth and 6.1% of firmwide revenue. Portfolio momentum is driven by flagship asset Taltz alongside rollouts of Ebglyss and Omvoh. Lilly continues building depth across oral and targeted immunology through acquired assets from DICE, Morphic, and Merida, broadening revenue exposure beyond its core GLP-1 diabetes and obesity pipeline.
    → Pipeline diversification into immunology expands non-incretin operating cash flow and buffers Eli Lilly's multiple against obesity drug concentration risk.
    Impact
    Eli Lilly's immunology segment reached $2.6 billion in first-half 2026 sales, representing 9% annual growth and 6.1% of firmwide revenue. Portfolio momentum is driven by flagship asset Taltz alongside rollouts of Ebglyss and Omvoh. Lilly continues building depth across oral and targeted immunology through acquired assets from DICE, Morphic, and Merida, broadening revenue exposure beyond its core GLP-1 diabetes and obesity pipeline.
    Affected
    LLYABBV
    Transmission
    Pipeline diversification into immunology expands non-incretin operating cash flow and buffers Eli Lilly's multiple against obesity drug concentration risk.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYnon-incretin revenue diversification and immunology margin expansionUp1-3mEli Lilly immunology revenue reached $2.6B in H1 2026, up 9% YoY.
    ABBVatopic dermatitis and IBD biologic competitive pricing pressureWatch1-3mEbglyss and Omvoh compete in core immunology indications against AbbVie portfolios.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month